JP2004500366A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004500366A5 JP2004500366A5 JP2001548141A JP2001548141A JP2004500366A5 JP 2004500366 A5 JP2004500366 A5 JP 2004500366A5 JP 2001548141 A JP2001548141 A JP 2001548141A JP 2001548141 A JP2001548141 A JP 2001548141A JP 2004500366 A5 JP2004500366 A5 JP 2004500366A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- binding
- polypeptide
- neutralizing antibody
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 description 36
- 238000000034 method Methods 0.000 description 25
- 241000711549 Hepacivirus C Species 0.000 description 12
- 230000003472 neutralizing effect Effects 0.000 description 11
- 229920001184 polypeptide Polymers 0.000 description 11
- 102000004196 processed proteins & peptides Human genes 0.000 description 11
- 108090000765 processed proteins & peptides Proteins 0.000 description 11
- 108010076039 Polyproteins Proteins 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 239000002157 polynucleotide Substances 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000008482 12E7 Antigen Human genes 0.000 description 2
- 108010020567 12E7 Antigen Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241001504519 Papio ursinus Species 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16823499P | 1999-12-01 | 1999-12-01 | |
| US18505500P | 2000-02-25 | 2000-02-25 | |
| PCT/US2000/042541 WO2001047551A2 (en) | 1999-12-01 | 2000-12-01 | Eliciting antibodies specific for hepatitis c virus (hcv) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004500366A JP2004500366A (ja) | 2004-01-08 |
| JP2004500366A5 true JP2004500366A5 (https=) | 2008-01-10 |
Family
ID=26863907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001548141A Pending JP2004500366A (ja) | 1999-12-01 | 2000-12-01 | Ｃ型肝炎ウイルス（ｈｃｖ）について特異的な抗体を誘発すること |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US7329408B2 (https=) |
| EP (1) | EP1233782B1 (https=) |
| JP (1) | JP2004500366A (https=) |
| AT (1) | ATE413190T1 (https=) |
| AU (1) | AU5442501A (https=) |
| CA (1) | CA2393251C (https=) |
| CY (1) | CY1108734T1 (https=) |
| DE (1) | DE60040755D1 (https=) |
| DK (1) | DK1233782T3 (https=) |
| ES (1) | ES2319727T3 (https=) |
| PT (1) | PT1233782E (https=) |
| WO (1) | WO2001047551A2 (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU1236801A (en) * | 1999-10-27 | 2001-05-08 | Chiron Corporation | Activation of hcv-specific t cells |
| US7329408B2 (en) * | 1999-12-01 | 2008-02-12 | Novartis Vaccines And Diagnostics, Inc. | Eliciting HCV-specific antibodies |
| AUPQ797700A0 (en) * | 2000-06-06 | 2000-06-29 | Austin Research Institute, The | Vaccine |
| SK15762003A3 (sk) * | 2001-06-29 | 2005-01-03 | Chiron Corporation | Kompozícia vakcíny HCV E1E2 |
| CU23244A1 (es) * | 2001-07-16 | 2007-10-17 | Ct Ingenieria Genetica Biotech | Formulacion vacunal potenciada por la combinacion de un adn con un antigeno |
| US7598362B2 (en) | 2001-10-11 | 2009-10-06 | Merck & Co., Inc. | Hepatitis C virus vaccine |
| EP2263687B1 (en) * | 2002-12-27 | 2015-03-25 | Novartis Vaccines and Diagnostics, Inc. | Immunogenic compositions containing phospholipid |
| WO2004065578A2 (en) * | 2003-01-14 | 2004-08-05 | Chiron Corporation | Microparticles comprising polynucleotide adsorbed on the surface of or entrapped within the microparticles |
| WO2004071414A2 (en) * | 2003-02-05 | 2004-08-26 | Genzyme Corporation | Therapeutic anti-hcv (al9) compounds |
| WO2004091491A2 (en) * | 2003-04-10 | 2004-10-28 | Transform Pharmaceuticals, Inc. | Profiling conformational variants, antibody compositions and methods of using the same |
| CA2523266A1 (en) * | 2003-04-25 | 2004-11-11 | Chiron Corporation | Compositions comprising cationic microparticles and hcv e1e2 dna and methods of use thereof |
| JP5557415B2 (ja) * | 2003-06-02 | 2014-07-23 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | 吸着させたトキソイドおよび多糖類含有抗原を含む微粒子に基づく免疫原性組成物 |
| CA2566725A1 (en) * | 2004-05-17 | 2005-12-01 | Chiron Corporation | Truncated hepatitis c virus ns5 domain and fusion proteins comprising same |
| US20080154210A1 (en) | 2004-05-28 | 2008-06-26 | Oryxe | Mixture for Transdermal Delivery of Low and High Molecular Weight Compounds |
| DE602005026545D1 (de) * | 2004-08-24 | 2011-04-07 | Tokyo Metropolitan Org Med Res | Modifizierte genomische rna des menschlichen hepatitis-c-virus mit autonomer replikationskompetenz |
| CA2587712C (en) * | 2004-11-18 | 2013-02-12 | National University Of Corporation Hiroshima University | Method and kit for expressing protein under regulation of the expression from repeated sequence formed by gene amplification and transformant |
| US8178086B2 (en) * | 2006-01-04 | 2012-05-15 | Novartis Vaccines And Diagnostics, Inc. | Activation of HCV specific T cells |
| US20100291545A1 (en) | 2007-07-25 | 2010-11-18 | Takaji Wakita | Antibody having inhibitory activity on infection with hepatitis c virus (hcv) and use thereof |
| EP2495256A4 (en) | 2009-10-30 | 2013-09-25 | Toray Industries | ANTIBODIES WITH HEMMETAL EFFECT ON INFECTIONS WITH HEPATITIS C VIRUS (HCV) AND ITS USE |
| CN104324373B (zh) * | 2010-11-26 | 2018-10-09 | 麦克法兰博尼特医学健康研究公司 | 组合物及其制备方法 |
| CN105658230B (zh) | 2013-08-29 | 2020-04-21 | 希望之城 | 细胞穿透缀合物及其使用方法 |
| US11260018B2 (en) | 2015-09-17 | 2022-03-01 | Jrx Biotechnology, Inc. | Approaches for improving skin hydration and moisturization |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5350671A (en) * | 1987-11-18 | 1994-09-27 | Chiron Corporation | HCV immunoassays employing C domain antigens |
| JPH02500880A (ja) * | 1987-11-18 | 1990-03-29 | カイロン コーポレイション | Ｎａｎｂｖの診断用薬およびワクチン |
| US5471330A (en) | 1993-07-29 | 1995-11-28 | Honeywell Inc. | Polysilicon pixel electrode |
| DE69534296T2 (de) * | 1994-07-29 | 2006-04-27 | Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville | Sezernierter E1/E2-Komplex des Hepatitis C-Virus, des aus C-terminal verkürzten Polypeptiden E1 und E2 erhalten ist |
| AU3241095A (en) | 1994-07-29 | 1996-03-04 | Chiron Corporation | Novel hepatitis c e1 and e2 truncated polypeptides and methods of obtaining the same |
| GB9416671D0 (en) | 1994-08-17 | 1994-10-12 | Biocine Spa | Assay |
| US6019980A (en) * | 1995-06-07 | 2000-02-01 | Connaught Laboratories Limited | Nucleic acid respiratory syncytial virus vaccines |
| DE69608122T3 (de) * | 1995-11-09 | 2011-06-16 | Microbiological Research Authority Camr, Salisbury | Mikroverkapselte dna zur impfung und gentherapie |
| US5939400A (en) * | 1996-02-26 | 1999-08-17 | The Board Of Trustees Of The Leland Stanford Junior University | DNA vaccination for induction of suppressive T cell response |
| DE69841015D1 (de) * | 1997-05-06 | 2009-09-10 | Novartis Vaccines & Diagnostic | Intrazelluläre herstellung von verkürztem hepatitis c-polypeptid e2 |
| WO1999004010A1 (en) * | 1997-07-18 | 1999-01-28 | Connaught Laboratories Limited | Nucleic acid vaccines encoding g protein of respiratory syncytial virus |
| WO1999030737A1 (en) * | 1997-12-16 | 1999-06-24 | Chiron Corporation | Use of microparticles combined with submicron oil-in-water emulsions |
| AU1236801A (en) * | 1999-10-27 | 2001-05-08 | Chiron Corporation | Activation of hcv-specific t cells |
| US7329408B2 (en) * | 1999-12-01 | 2008-02-12 | Novartis Vaccines And Diagnostics, Inc. | Eliciting HCV-specific antibodies |
-
2000
- 2000-12-01 US US09/728,423 patent/US7329408B2/en not_active Expired - Lifetime
- 2000-12-01 DK DK00993586T patent/DK1233782T3/da active
- 2000-12-01 AU AU54425/01A patent/AU5442501A/en not_active Abandoned
- 2000-12-01 PT PT00993586T patent/PT1233782E/pt unknown
- 2000-12-01 ES ES00993586T patent/ES2319727T3/es not_active Expired - Lifetime
- 2000-12-01 WO PCT/US2000/042541 patent/WO2001047551A2/en not_active Ceased
- 2000-12-01 EP EP00993586A patent/EP1233782B1/en not_active Expired - Lifetime
- 2000-12-01 AT AT00993586T patent/ATE413190T1/de active
- 2000-12-01 JP JP2001548141A patent/JP2004500366A/ja active Pending
- 2000-12-01 CA CA2393251A patent/CA2393251C/en not_active Expired - Fee Related
- 2000-12-01 DE DE60040755T patent/DE60040755D1/de not_active Expired - Lifetime
-
2007
- 2007-12-13 US US12/001,920 patent/US20080095800A1/en not_active Abandoned
-
2009
- 2009-01-27 CY CY20091100101T patent/CY1108734T1/el unknown
-
2010
- 2010-08-30 US US12/871,035 patent/US20110159039A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2004500366A5 (https=) | ||
| CA2393251A1 (en) | Eliciting hcv-specific antibodies | |
| Walayat et al. | Recent advances in vaccination of non-responders to standard dose hepatitis B virus vaccine | |
| Lechmann et al. | Vaccine development for hepatitis C | |
| Li et al. | Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection | |
| CN105431535A (zh) | 疟疾疫苗 | |
| EP2419124A2 (en) | Foot-and mouth disease marker vaccine | |
| Olivera et al. | Protective cellular immune response against hepatitis C virus elicited by chimeric protein formulations in BALB/c mice | |
| Boudewijns et al. | A novel therapeutic HBV vaccine candidate induces strong polyfunctional cytotoxic T cell responses in mice | |
| ES2551113T3 (es) | Proteína E1E2 del VHC adyuvantada con MF59 más vector de alfavirus que codifica E1E2 del VHC para provocar linfocitos T específicos del VHC | |
| JP6259831B2 (ja) | Ｃ型肝炎ウイルスに対するキメラワクチン抗原 | |
| Koshy et al. | Evaluation of hepatitis C virus protein epitopes for vaccine development | |
| Balakrishnan et al. | Discovery of HCV Vaccine: Where do we stand? | |
| Garcia et al. | An overview of hepatitis C vaccines | |
| US20100316669A1 (en) | Vaccine formulation potentiated by the combination of dna and an antigen | |
| CN1984677A (zh) | 截短的丙肝病毒ns5结构域以及含有该截短结构域的融合蛋白 | |
| Alvarez-Lajonchere et al. | Advances in DNA immunization against hepatitis C virus infection: Opportunities and challenges | |
| CN1809584B (zh) | 含有阳离子微粒和hcv e1e2 dna的组合物及其使用方法 | |
| Akbar et al. | Innovative Therapies Targeting the Virus and the Host for Treating Chronic Hepatitis B Virus Infection: From Bench to Bedside. Vaccines 2022; 10: 746 | |
| JP2001517447A5 (https=) | ||
| Martínez‐Donato et al. | Ratio of HCV structural antigens in protein‐based vaccine formulations is critical for functional immune response induction | |
| Morales | Ultrastructural and immunological characterization of hepatitis C core protein-dna plasmid complexes | |
| Chuai et al. | HBV antigen and DNA loss from mouse serum is associated with novel vaccine-induced HBV surface antigen-specific cell-mediated immunity and cytokine production | |
| Kerth et al. | Therapeutic hepatitis B vaccine employing DNA prime–MVA boost scheme requires additional priming with recombinant HBsAg to elicit an adequate antibody response | |
| Musacchio et al. | Novel knowledge about the influence of hepatitis C virus structural proteins ratio in vaccine preparations to induce a protective immune response in a challenge model with a surrogate virus |